Multidimensional Evaluation of Lisdexamfetamine: Pharmacology, Therapeutic Use, Toxicity and Forensic Implications
Basic & Clinical Pharmacology & Toxicology · 2025
DOI: 10.1111/bcpt.70111 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2025. Verfasst von Mariana Silva-Carvalho und 3 weiteren Autor:innen. Beteiligte Einrichtung: Associate Laboratory i4HB-Institute for Health and Bioeconomy, University Institute of Health Sciences-IUCS-CESPU, Gandra, Portugal. Hauptthemen laut MEDLINE: Lisdexamfetamine Dimesylate, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity. Die Arbeit nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Lisdexamfetamine (LDX), a prodrug of d ‐amphetamine, is widely used in the pharmacological treatment of neuropsychiatric disorders such as attention‐deficit/hyperactivity disorder (ADHD) and binge eating disorder (BED). Chemically, it consists of the amino acid lysine linked to d ‐amphetamine. Its enzymatic conversion to d ‐amphetamine sets the stage for a prolonged and controlled release, influencing its clinical profile and differentiating it from other stimulant medications. As a central nervous system stimulant, LDX primarily acts by increasing the release of neurotransmitters, particularly dopamine and noradrenaline, in the brain. Clinically, this enhanced availability of neurotransmitters is believed to contribute to improvements in attention, focus and impulse control in individuals with ADHD. The side effects of LDX include insomnia, decreased appetite, weight loss and xerostomia. This work reviews the pharmacological mechanisms, clinical applications and forensic considerations associated with its use. It is expected that clinicians, researchers and policymakers have a comprehensive understanding of the pharmacological and toxicological aspects of LDX.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Associate Laboratory i4HB-Institute for Health and Bioeconomy, University Institute of Health Sciences-IUCS-CESPU, Gandra, Portugal.
- UCIBIO-Research Unit on Applied Molecular Biosciences, Translational Toxicology Research Laboratory (1H-TOXRUN), University Institute of Health Sciences (IUCS-CESPU), Gandra, Portugal.
- REQUIMTE/LAQV, ESS, Polytechnic of Porto, Porto, Portugal.
- Associate Laboratory i4HB-Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, Porto, Portugal.
- UCIBIO-Applied Molecular Biosciences Unit, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Porto, Portugal.
- Department of Public Health and Forensic Sciences and Medical Education, Faculty of Medicine, University of Porto, Porto, Portugal.
ORCID-Profile: Mariana Silva-Carvalho, Diana Dias da Silva, Ricardo Jorge Dinis-Oliveira
Zitieren
APA
Silva-Carvalho, M., Barbosa, D. J., Dias da Silva, D., & Dinis-Oliveira, R. J. (2025). Multidimensional Evaluation of Lisdexamfetamine: Pharmacology, Therapeutic Use, Toxicity and Forensic Implications. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70111
Vancouver
Silva-Carvalho M, Barbosa DJ, Dias da Silva D, Dinis-Oliveira RJ. Multidimensional Evaluation of Lisdexamfetamine: Pharmacology, Therapeutic Use, Toxicity and Forensic Implications. Basic & Clinical Pharmacology & Toxicology. 2025. doi:10.1111/bcpt.70111
BibTeX
@article{SilvaCarvalho2025,
author = {Silva-Carvalho, Mariana and Barbosa, Daniel José and Dias da Silva, Diana and Dinis-Oliveira, Ricardo Jorge},
title = {Multidimensional Evaluation of Lisdexamfetamine: Pharmacology, Therapeutic Use, Toxicity and Forensic Implications},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2025},
doi = {10.1111/bcpt.70111}
}
EUVIMED